Xeris Biopharma Share Price (NASDAQ: XERS)

$7.83

▲

-0.07

(-0.89%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Xeris Biopharma Stock chart to analyse performance

Xeris Biopharma stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$7.68
Today's High:$7.88
$7.83
1.92%
Downside
Day's Volatility :2.54%
Upside
0.63%
52 Weeks Low:$2.48
52 Weeks High:$8.02
$7.83
68.33%
Downside
52 Weeks Volatility :69.08%
Upside
2.37%

Xeris Biopharma Stock Returns

Period	Xeris Biopharma Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	54.95%	3.6%	0.0%
6 Months	112.06%	-7.7%	0.0%
1 Year	178.47%	-12.6%	0.0%
3 Years	368.56%	9.5%	-4.7%

Xeris Biopharma Holdings Inc Key Stats

Check Xeris Biopharma key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.9
Open	$7.88
Today's High	$7.88
Today's Low	$7.68
Market Capitalization	$1.3B
Today's Volume	$1.5M
52 Week High	$8.02
52 Week Low	$2.48
Revenue TTM	$246.0M
EBITDA	$8.4M
Earnings Per Share (EPS)	$-0.2
Profit Margin	-13.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-617.16%

Stock Returns calculator for Xeris Biopharma Stock including INR - Dollar returns

The Xeris Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Xeris Biopharma investment value today

Current value as on today

₹2,83,932

Returns

₹1,83,932

(+183.93%)

Returns from Xeris Biopharma Stock

₹1,78,648 (+178.65%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Xeris Biopharma Stock

73%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Xeris Biopharma Stock from India on INDmoney has increased by 73% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Xeris Biopharma Holdings Inc

Name
Holdings %
Charles Schwab Investment Management Inc
0.35%

Analyst Recommendation on Xeris Biopharma Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Xeris Biopharma(by analysts ranked 0 to 5 stars)

Xeris Biopharma Share Price Target

What analysts predicted

Upside of 14.94%

Target:

$9.00

Current:

$7.83

Xeris Biopharma share price target is $9.00, a slight Upside of 14.94% compared to current price of $7.83 as per analysts' prediction.

Xeris Biopharma Stock Insights

Price Movement
In the last 1 month, XERS stock has moved up by 52.5%
Increasing Revenue
Revenue is up for the last 6 quarters, 40.63M → 71.53M (in $), with an average increase of 10.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -9.22M → -1.92M (in $), with an average increase of 378.2% per quarter

Xeris Biopharma Holdings Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$2.7M	↑ 10.43%
Net Income	$-125.6M	↑ 109.02%
Net Profit Margin	-4.6K%	↓ 2176.2%

	FY20	Y/Y Change
Revenue	$20.2M	↑ 640.45%
Net Income	$-91.1M	↓ 27.42%
Net Profit Margin	-452.2%	↑ 4161.32%

	FY21	Y/Y Change
Revenue	$49.6M	↑ 146.04%
Net Income	$-122.7M	↑ 34.66%
Net Profit Margin	-247.48%	↑ 204.72%

	FY22	Y/Y Change
Revenue	$110.2M	↑ 122.32%
Net Income	$-94.7M	↓ 22.87%
Net Profit Margin	-85.86%	↑ 161.62%

	FY23	Y/Y Change
Revenue	$163.9M	↑ 48.68%
Net Income	$-62.3M	↓ 34.23%
Net Profit Margin	-37.98%	↑ 47.88%

	FY24	Y/Y Change
Revenue	$203.1M	↑ 23.89%
Net Income	$-54.8M	↓ 11.92%
Net Profit Margin	-27.0%	↑ 10.98%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$40.6M	↓ 8.45%
Net Income	$-19.0M	↑ 41.75%
Net Profit Margin	-46.71%	↓ 16.55%

	Q2 FY24	Q/Q Change
Revenue	$48.1M	↑ 18.28%
Net Income	$-15.0M	↓ 20.94%
Net Profit Margin	-31.22%	↑ 15.49%

	Q3 FY24	Q/Q Change
Revenue	$54.3M	↑ 12.91%
Net Income	$-15.7M	↑ 4.89%
Net Profit Margin	-29.0%	↑ 2.22%

	Q4 FY24	Q/Q Change
Revenue	$60.1M	↑ 10.74%
Net Income	$-5.1M	↓ 67.51%
Net Profit Margin	-8.51%	↑ 20.49%

	Q1 FY25	Q/Q Change
Revenue	$60.1M	↑ 0.03%
Net Income	$-9.2M	↑ 80.32%
Net Profit Margin	-15.34%	↓ 6.83%

	Q2 FY25	Q/Q Change
Revenue	$71.5M	↑ 19.0%
Net Income	$-1.9M	↓ 79.09%
Net Profit Margin	-2.7%	↑ 12.64%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.1M	↓ 53.82%

	FY20	Y/Y Change
Profit	$10.8M	↑ 867.56%

	FY21	Y/Y Change
Profit	$36.3M	↑ 235.01%

	FY22	Y/Y Change
Profit	$87.6M	↑ 141.55%

	FY23	Y/Y Change
Profit	$135.3M	↑ 54.39%

	FY24	Y/Y Change
Profit	$166.2M	↑ 22.89%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$34.7M	↑ 1.64%

	Q2 FY24	Q/Q Change
Profit	$37.6M	↑ 8.36%

	Q3 FY24	Q/Q Change
Profit	$40.7M	↑ 8.28%

	Q4 FY24	Q/Q Change
Profit	$50.6M	↑ 24.45%

	Q1 FY25	Q/Q Change
Profit	$51.4M	↑ 1.52%

	Q2 FY25	Q/Q Change
Profit	$56.9M	↑ 10.78%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-104.3M	↑ 85.41%
Investing Cash Flow	$-2.4M	↓ 96.51%
Financing Cash Flow	$80.5M	↓ 37.19%

	FY20	Y/Y Change
Operating Cash Flow	$-80.6M	↓ 22.8%
Investing Cash Flow	$-27.4M	↑ 1050.02%
Financing Cash Flow	$126.1M	↑ 56.54%

	FY21	Y/Y Change
Operating Cash Flow	$-95.5M	↑ 18.59%
Investing Cash Flow	$98.0M	↓ 457.47%
Financing Cash Flow	$27.2M	↓ 78.39%

	FY22	Y/Y Change
Operating Cash Flow	$-102.9M	↑ 7.7%
Investing Cash Flow	$34.5M	↓ 64.82%
Financing Cash Flow	$127.5M	↑ 367.84%

	FY23	Y/Y Change
Operating Cash Flow	$-47.0M	↓ 54.3%
Investing Cash Flow	$-6.0M	↓ 117.42%
Financing Cash Flow	$-1.6M	↓ 101.27%

	FY24	Y/Y Change
Operating Cash Flow	$-37.0M	↓ 21.36%
Investing Cash Flow	$4.9M	↓ 181.33%
Financing Cash Flow	$36.2M	↓ 2342.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-20.3M	↓ 422.99%
Investing Cash Flow	$-19.7M	↓ 232.16%
Financing Cash Flow	$35.2M	↓ 71924.49%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	↓ 49.03%
Investing Cash Flow	$4.6M	↓ 123.42%
Financing Cash Flow	$659.0K	↓ 98.13%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-8.3M	↓ 19.74%
Investing Cash Flow	$9.9M	↑ 115.38%
Financing Cash Flow	$-83.0K	↓ 112.59%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.0M	↓ 123.78%
Investing Cash Flow	$10.0M	↑ 1.03%
Financing Cash Flow	$398.0K	↓ 579.52%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-10.0M	↓ 607.9%
Investing Cash Flow	$-13.0K	↓ 100.13%
Financing Cash Flow	$-3.1M	↓ 888.19%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$182.0K	↓ 101.81%
Investing Cash Flow	$-279.0K	↑ 2046.15%
Financing Cash Flow	$942.0K	↓ 130.03%

Xeris Biopharma Technicals Summary

Sell

Neutral

Buy

Xeris Biopharma is currently in a neutral trading position according to technical analysis indicators.

Xeris Biopharma Holdings Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Xeris Biopharma Holdings Inc	53.73%	112.06%	178.47%	368.56%	329.95%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.98%	-0.05%	-6.32%
Beone Medicines Ltd	1.77%	24.81%	59.79%	78.52%	26.86%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-21.18%	38.72%	40.03%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	69.91%	115.96%	236.5%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Xeris Biopharma Holdings Inc	NA	NA	NA	-0.01	-6.17	-0.01	NA	-0.12
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Xeris Biopharma Holdings Inc	Buy	$1.3B	329.95%	NA	-13.01%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-6.32%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	26.86%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	40.03%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	236.5%	NA	-12.96%

About Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Organization	Xeris Biopharma
Employees	394
CEO	Mr. John P. Shannon
Industry	Health Technology

Key Management of Xeris Biopharma Holdings Inc

Name	Title
Mr. John P. Shannon	CEO & Director
Mr. Kevin McCulloch	President & COO
Mr. Steven M. Pieper	Chief Financial Officer
Ms. Beth P. Hecht J.D.	Chief Legal Officer & Corporate Secretary
Mr. Paul R. Edick J.D.	Senior Advisor
Ms. Allison Wey	Senior Vice President of Investor Relations & Corporate Communications
Mr. Brian Conner	SVP of Quality and Chief Compliance & Risk Officer
Ms. Kendal Korte	Senior Vice President of Human Resources
Dr. Anh Nguyen M.B.A., M.D.	Chief Medical Officer

Important FAQs about investing in XERS Stock from India :

What is Xeris Biopharma share price today?

Xeris Biopharma share price today is $7.83 as on August 30, 2025 at 1:29 am IST at the close of the market. Xeris Biopharma share today touched a day high of $7.88 and a low of $7.68.

What is the 52 week high and 52 week low for Xeris Biopharma share?

Xeris Biopharma share touched a 52 week high of $8.02 and a 52 week low of $2.48. Xeris Biopharma stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $7.83, lower by 2.37% versus the 52 week high.

How to invest in Xeris Biopharma Stock (XERS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Xeris Biopharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Xeris Biopharma Shares that will get you 0.1916 shares as per Xeris Biopharma share price of $7.83 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Xeris Biopharma Stock (XERS) from India?

Indian investors can start investing in Xeris Biopharma (XERS) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Xeris Biopharma stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Xeris Biopharma share’s latest price of $7.83 as on August 30, 2025 at 1:29 am IST, you will get 1.2771 shares of Xeris Biopharma. Learn more about fractional shares .

What are the returns that Xeris Biopharma has given to Indian investors in the last 5 years?

Xeris Biopharma stock has given 329.95% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?